Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
H. Mursaloglu (Istanbul, Turkey), C. Akin (Istanbul, Turkey), C. Yilmaz (Istanbul, Turkey), P. Ergenekon (Istanbul, Turkey), Y. Gokdemir (Istanbul, Turkey), E. Erdem Eralp (Istanbul, Turkey), F. Karakoc (Istanbul, Turkey), A. Karahasan (Istanbul, Turkey), B. Karadag (Istanbul, Turkey). A review of treatment regimens at first isolation of PA in a single cystic fibrosis center. 690

Member's Comments

No comment yet.

Related content which might interest you: The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis Source: Breathe, 17 (1) 210013; 10.1183/20734735.0013-2021 Year: 2021 Feasibility study of an intervention to increase treatment adherence in children with cystic fibrosis (CF) Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis Year: 2019 The need for lung transplantation in cystic fibrosis (CF) in the era of new treatment Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs Year: 2020 A review of 50 cystic fibrosis (CF) patients referred to a UK transplant centre Source: Eur Respir J 2001; 18: Suppl. 33, 298s Year: 2001 Health-economic aspects of cystic fibrosis screening and therapy Source: Eur Respir Monogr 2014; 64: 304-319 Year: 2014 Evaluation of adherence to medication treatment in pediatric patients with cystic fibrosis; a cross-sectional study Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis Year: 2019 A UK experience of temocillin in the treatment of adult cystic fibrosis patients Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008 Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 342s Year: 2002 Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients? Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 New cystic fibrosis therapy targets Source: Research Seminar 2014 - Protein quality control in lung disease Year: 2014 Update on new treatments for cystic fibrosis Source: Virtual Congress 2020 – Updates in cystic fibrosis Year: 2020 Oral L-arginine therapy in patients with cystic fibrosis: a pilot study Source: Eur Respir J 2002; 20: Suppl. 38, 340s Year: 2002 Gene therapy for cystic fibrosis: successes and challenges Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=79 Year: 2006 In vitro assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis Source: Eur Respir J, 59 (2) 2102380; 10.1183/13993003.02380-2021 Year: 2022 Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 A new paradigm for the management of children with cystic fibrosis at home: experiences from a Dutch cystic fibrosis clinic Source: Virtual Congress 2021 – New technologies for the management of children with respiratory diseases Year: 2021 Long-term evaluation of the response to aggressive treatment at the first colonization of P.aeruginosa in cystic fibrosis (CF) Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001 Home intravenous antibiotic treatments in cystic fibrosis adult patients Source: Eur Respir J 2002; 20: Suppl. 38, 158s Year: 2002